Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Therapeutic proteins are proteins that are engineered in the laboratory for pharmaceutical use, including non-covalent binders, therapeutic proteins such as enzymes and albumin are having properties such as breaking of covalent bongs and therefore has wide application of treatment .Therapeutic proteins are highly effective in vivo and in-vitro treatment of diseases. Oral vaccines are biologically prepared products, which provide active acquired immunity to diseases such as cholera, polio, rotavirus, smallpox, yellow fever, and others. An oral vaccine comprise an agent resembling to the disease causing microorganism. The vaccines are generally developed from live attenuated or killed forms of the disease causing microorganism, its toxins, or its surface proteins.
Figure 1. Global Therapeutic Proteins and Oral Vaccines Market Value (US$ Mn), 2016-2027
The global therapeutic proteins and oral vaccines market size is estimated to be valued at US$ 201,042.7 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).
The increasing investments by key players for the development of promising therapies for treatment of different disease conditions is expected to drive the market growth over the forecast period. For instance, in March 2020, research scientists at Migal Galilee Research Institute Ltd, the research and development center of MigVax Ltd, announced to develop a oral vaccine for a deadly coronavirus virus affecting poultry could be adapted for human use against the novel coronavirus known as 2019-nCoV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Moreover, increasing prevalence of oncology disease is expected to drive growth of the global therapeutic proteins and oral vaccines market. For instance, according to the World Health Organization report published in September 2018, cancer is the second leading cause of death globally, with around 70% of deaths occurring in low and middle income countries.
Therapeutic Proteins and Oral Vaccines Market Report Coverage
||Market Size in 2020:
||US$ 201,042.7 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 316,684.7 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of the Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Class:
- Therapeutic Proteins: Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, Others.
- Oral Vaccines: Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, Others.
- By Application: Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
- By Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa
Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc. , TransAlgae, MigVax Ltd, and Lumen Bioscience, Inc
- Increasing prevalence of chronic diseases
- Rising number of clinical trials by major companies
- Key players focusing on increasing robust pipeline of biologics
- Key players focusing on strategies such as collaborations
|Restraints & Challenges:
- Stringent regulatory scenario and
- lower availability and affordability of therapeutic proteins in lower income countries
Global Therapeutic Proteins and Oral Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic
The increasing prevalence of COVID-19 has caused production factories to shutdown in almost all sectors, and also affected the supply of raw materials and Active Pharmaceutical Ingredients (API) of the manufacturing companies across the globe. Moreover, various guidelines have been implemented by regulatory authorities for manufacturing of active pharmaceutical ingredients and pharmaceutical products to avoid the spread of COVID-19 and also to reduce the contamination of active pharmaceutical ingredients during the manufacturing process of pharmaceuticals products such as vaccines, tablets, and others.
According to the U.S. Food Drug and Administration’s report of June 2020, owing to the COVID-19 public health emergency, drug manufacturers are required to abide by the following current good manufacturing practice (CGMP) regulations and recommendations regarding restriction of sick employees from production areas. 1) Any employee or worker in a production unit should be medically evaluated for infectious diseases such as COVID-19. 2) If any of individual is exhibiting COVID-19 symptoms, they shall be restricted from entering the production house premises of the company to prevent contamination of drugs and active pharmaceutical ingredients (API).
Thus, the COVID-19 pandemic has negatively affected the Global therapeutic protein and oral vaccine market.
Figure 2. Global Therapeutic Proteins and Oral Vaccines Market Share (%) by Region, 2020
In North America, increasing prevalence of cardiovascular disorders (CVDs) such as coronary heart failure and others is expected to drive the demand of therapeutic proteins for the treatment of cardiovascular diseases, which in turn is expected to boost growth of the global therapeutic proteins and oral vaccines market over the forecast period. For instance, according to the American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. suffered from some form of CVD or the after-effects of stroke.
Moreover, in Europe, increasing number of conferences and symposiums conducted in Europe, which are focused on spreading knowledge about recent advancements in biopharmaceutical field is expected to create a lucrative environment for the market growth. For instance, in September 2018, 6th European Biopharma Congress was held at Amsterdam, Netherlands. The subject of this conference was novel strategies and advancements in biopharmaceutics. Researchers and scientists participating in this seminar discussed on cell therapy, biotechnology, therapeutic biological products, gene therapy, biosimilars, drug discovery, and clinical trials.
Furthermore, Middle-to-lower income countries such as India, Indonesia, Bangladesh, Mexico, Brazil, and certain European countries do not have proper availability of biologics due to high cost and lack of reimbursement for biologics. Therefore, lower availability and affordability of biologics in middle and lower income countries are expected to hamper the biologics market growth over the forecast period. For instance, according to article 'Affordability Issues of Biotech Drugs in Low- and Middle-Income Countries (LMICs)' published in Drug Designing and Intellectual Properties International Journal 2019, in India alone, as many as 63 million people are forced into poverty every year, owing to very high health expenses, the majority of which are out-of-pocket payments for medicines. These factors are expected to restraint the global therapeutic proteins and oral vaccines market.
Major players operating in global therapeutic proteins and oral vaccines market include Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd, and Lumen Bioscience, Inc